Atazanavir demonstrates antiviral efficacy and a favorable lipid profile at 48 weeks.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019888:Nelfinavir / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D017320:HIV Protease Inhibitors; D002784:Cholesterol; D019888:Nelfinavir